- Home
- ANNX vs MMD Comparison
ANNX vs MMD Comparison
Compare ANNX & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- MMD
- Stock Information
- Founded
- ANNX 2011
- MMD 2012
- Country
- ANNX United States
- MMD United States
- Employees
- ANNX N/A
- MMD N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- MMD Investment Managers
- Sector
- ANNX Health Care
- MMD Finance
- Exchange
- ANNX Nasdaq
- MMD Nasdaq
- Market Cap
- ANNX 334.1M
- MMD 284.7M
- IPO Year
- ANNX 2020
- MMD N/A
- Fundamental
- Price
- ANNX $2.92
- MMD $15.13
- Analyst Decision
- ANNX Strong Buy
- MMD
- Analyst Count
- ANNX 4
- MMD 0
- Target Price
- ANNX $13.00
- MMD N/A
- AVG Volume (30 Days)
- ANNX 1.9M
- MMD 74.7K
- Earning Date
- ANNX 11-10-2025
- MMD 01-01-0001
- Dividend Yield
- ANNX N/A
- MMD 4.88%
- EPS Growth
- ANNX N/A
- MMD N/A
- EPS
- ANNX N/A
- MMD N/A
- Revenue
- ANNX N/A
- MMD N/A
- Revenue This Year
- ANNX N/A
- MMD N/A
- Revenue Next Year
- ANNX N/A
- MMD N/A
- P/E Ratio
- ANNX N/A
- MMD N/A
- Revenue Growth
- ANNX N/A
- MMD N/A
- 52 Week Low
- ANNX $1.29
- MMD $14.30
- 52 Week High
- ANNX $6.93
- MMD $17.67
- Technical
- Relative Strength Index (RSI)
- ANNX 45.55
- MMD 55.17
- Support Level
- ANNX $2.66
- MMD $15.02
- Resistance Level
- ANNX $3.03
- MMD $15.20
- Average True Range (ATR)
- ANNX 0.24
- MMD 0.11
- MACD
- ANNX -0.04
- MMD -0.01
- Stochastic Oscillator
- ANNX 26.98
- MMD 78.26
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.